Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma.
Int J Clin Oncol
; 18(1): 68-74, 2013 Feb.
Article
em En
| MEDLINE
| ID: mdl-22068465
ABSTRACT
BACKGROUND:
The prophylactic effect of postoperative interferon on recurrence and distant metastasis in stage II or III renal cell carcinoma is unclear. In most studies, interferon has been administered for 6 months or less. Therefore, we performed a clinical study of the efficacy of 1-year postoperative administration of natural interferon α, which is generally used in Japan.METHODS:
The subjects were patients diagnosed with stage II or III renal cell carcinoma who underwent radical nephrectomy. The subjects were randomly allocated to receive an intramuscular injection of natural interferon α (3 million to 6 million units) 3 times a week for 1 year or to receive follow-up observation until recurrence or metastasis occurred. Chest and abdominal CT were performed once yearly for all patients. The primary endpoint was progression-free survival.RESULTS:
From September 2001 to August 2006, a total of 107 patients were registered, but 7 subsequently withdrew from the study. Therefore, 100 patients were included in the analysis. The primary endpoint of progression-free survival did not differ significantly between the groups that received natural interferon α or follow-up observation (p = 0.456, log-rank test). However, peak hazards of progression in the interferon group were delayed for about 6-10 months compared with the observation group.CONCLUSION:
Progression-free survival showed no improvement after administration of natural interferon α to patients with stage II or III renal cell carcinoma for 1 year after radical nephrectomy. The peak hazards of progression might be delayed by about 6 months by interferon administration.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
1_ASSA2030
/
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Proteínas Recombinantes
/
Carcinoma de Células Renais
/
Interferon-alfa
/
Neoplasias Renais
/
Recidiva Local de Neoplasia
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Aged
/
Aged80
/
Humans
/
Middle aged
País/Região como assunto:
Asia
Idioma:
En
Revista:
Int J Clin Oncol
Ano de publicação:
2013
Tipo de documento:
Article